Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT05474703 |
Other study ID # |
Duphastonversusmirena |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
February 20, 2022 |
Est. completion date |
August 10, 2022 |
Study information
Verified date |
July 2022 |
Source |
Kanuni Sultan Suleyman Training and Research Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
This study was retrospectively collected from patients who were diagnosed with abnormal
uterine bleeding and received oral dydrogesterone therapy for at least six months or who were
administered an intrauterine device containing levonorgestrel at least six months ago, and
prospectively Short form 36 (P-36); It covers the comparison of the Quality of Life Scale and
the Female Sexual Function Scale (FSFI) by asking over the phone.
Description:
This study aimed to apply to the Gynecology and Obstetrics Clinic of Istanbul Health Sciences
University Kanuni Sultan Süleyman Training and Research Hospital between August 2020 and
December 2021, diagnosed with abnormal uterine bleeding between the ages of 18-45 and receive
oral dydrogesterone treatment for at least six months or an intrauterine device releasing
levonorgestrel. A total of 171 sexually active female patients who were treated were
included. Of the patients participating in the study, 86 comprised two groups of patients who
received LNG-IUD, and 85 received oral dydrogesterone treatment.
This study was retrospectively collected from patients who were diagnosed with abnormal
uterine bleeding and received oral dydrogesterone therapy for at least six months or who had
an intrauterine device containing levonorgestrel at least six months ago, and prospectively
Short form 36 (P-36); It covers the comparison of the Quality of Life Scale and the Female
Sexual Function Scale (FSFI) by asking over the phone.
Patients outside the age range of 18-45, sexually inactive patients, patients in pregnancy or
postpartum, patients with known malignancy history or suspected malignancy, patients with
abnormal smear results, patients with bleeding diathesis, patients using drugs that may cause
vaginal bleeding, gynecological patients. Patients with any organic pathology that could
explain bleeding on examination, patients with levonorgestrel-releasing intrauterine mediator
dislocated, and patients who had previously received different treatments for abnormal
uterine bleeding were not included.